Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Department of Medical Microbiology & Infectious Diseases, Erasmus University Medical Center Rotterdam (Erasmus MC), Rotterdam, The Netherlands.
Future Microbiol. 2018 Nov;13:1683-1692. doi: 10.2217/fmb-2018-0194. Epub 2018 Nov 30.
Respiratory tract infections are one of the most frequent infections worldwide, with an increasing number being associated with (multiple) antibiotic-resistant pathogens. Improved treatment requires the development of new therapeutic strategies, including the possible development of antibiotic-nanomedicines. Antibiotic-nanomedicines comprise antibiotic molecules coupled to nanocarriers via surface adsorption, surface attachment, entrapment or conjugation and can be administered via aerosolization. The efficacy and tolerability of this approach has been shown in clinical studies, with amikacin liposome inhalation suspension being the first inhalatory antibiotic-nanomedicine approved by the US FDA. In this special report, we summarize and discuss the potential value and the clinical status of antibiotic-nanomedicines for the treatment of (antibiotic-resistant) respiratory tract infections.
呼吸道感染是全球最常见的感染之一，越来越多的感染与（多种）抗生素耐药病原体有关。为了改善治疗效果，需要开发新的治疗策略，包括开发抗生素-纳米药物的可能性。抗生素-纳米药物由通过表面吸附、表面附着、包封或缀合与纳米载体偶联的抗生素分子组成，可以通过雾化给药。临床研究已经证明了这种方法的疗效和耐受性，其中阿米卡星脂质体吸入混悬液是美国 FDA 批准的第一种吸入用抗生素-纳米药物。在本特别报告中，我们总结并讨论了抗生素-纳米药物治疗（抗生素耐药）呼吸道感染的潜在价值和临床现状。
